#GynCsm
LightNews LightNews
onclive.bsky.social
How are ADCs and biomarker-driven approaches shaping gynecologic oncology practice? @uclahealth.org @mdanderson.bsky.social #gyncsm #oncology

Find out what experts have to say by signing up to read our exclusive feature! www.onclive.com/view/refined...
November 5, 2026 at 12:59 PM
onclive.bsky.social
Just in from #ESMO2026: Sac-TMT improved PFS and OS vs treatment of physician’s choice in previously treated, advanced/recurrent endometrial cancer; the agent is under @fda.gov priority review for this indication. @myesmo.bsky.social #gyncsm #oncology

Full story ➡️: www.onclive.com/view/sac-tmt...
October 26, 2026 at 6:38 PM
onclive.bsky.social
New phase 1 data presented at @myesmo.bsky.social #ESMO26 show a 48% response rate with INCB123667 plus bevacizumab in heavily pretreated, cyclin E1–overexpressing platinum-resistant ovarian cancer.

Read more: www.onclive.com/view/incb123... #gyncsm #oncology
October 24, 2026 at 2:14 PM
onclive.bsky.social
Poll Recap: Readers share their opinions on some of the most talked-about gynecologic cancer abstracts and topics they’re looking forward to seeing at #ESMO2026. @myesmo.bsky.social #gyncsm #oncology

Full story ➡️: www.onclive.com/view/poll-re...
Poll Results Highlight Gynecologic Cancer Abstracts of Interest at ESMO 2026 | OncLive
Readers share their opinions on some of the most talked-about gynecologic cancer abstracts they’re looking forward to seeing at ESMO 2026.
www.onclive.com
October 23, 2026 at 11:20 AM
emilydrake.ca
Q4: What are the next steps for #AYACancer innovation? #AYACSM

#GYNCSM #ONCOLOGY #CANCERRESEARCH #TYACANCER #BTSM #BCSM #LCSM
October 14, 2026 at 12:46 AM
emilydrake.ca
Q3: Does social media have a role in helping organizations and HCPs be more innovative? How? #AYACSM

#OncSky #HCSMCA #HCSM #LCSM #AMSM #BTSM #BCSM #GYNCSM
October 14, 2026 at 12:36 AM
onclive.bsky.social
📰 Botensilimab/balstilimab produced an estimated 3-year OS rate of 48% in heavily pretreated recurrent ovarian cancer in the ovarian cohort of the phase 1b C-800-01 trial. @danafarber.bsky.social #IGCS2026 #gyncsm #oncology

Read more ➡️: www.onclive.com/view/botensi...
Botensilimab Plus Balstilimab Yields Durable OS in Recurrent Ovarian Cancer | OncLive
The estimated 3-year OS rate with botensilimab plus balstilimab was 48% in heavily pretreated recurrent ovarian cancer in the phase 1b C-800-01 trial.
www.onclive.com
October 5, 2026 at 3:44 PM
onclive.bsky.social
📈 The IDMC overseeing an ongoing phase 2 MRD translational study of IMNN-001 in newly diagnosed advanced ovarian cancer has recommended the trial continue without modification. #gyncsm #oncology

More insights ➡️: www.onclive.com/view/idmc-re...
IDMC Recommends Continuation of Phase 2 MRD Study of IMNN-001 in Advanced Ovarian Cancer | OncLive
An IDMC recommended continuing a phase 2 minimal residual disease study of IMNN-001 without modification following a favorable safety review.
www.onclive.com
September 23, 2026 at 4:29 PM
onclive.bsky.social
Responses to ADC TUB-040 did not differ by NaPi2b expression level in platinum-resistant ovarian cancer, supporting a biomarker-unrestricted development path, according to Toon Van Gorp, MD, PhD. @ascocancer.bsky.social #ASCO26 #gyncsm #oncology

More insights ➡️: www.onclive.com/view/napista...
NAPISTAR-1-01 Data Support Rapid TUB-040 Development in Biomarker-Unrestricted Ovarian Cancer | OncLive
Toon Van Gorp, MD, PhD, discusses key data with TUB-040 in platinum-resistant ovarian cancer and next steps for development.
www.onclive.com
September 21, 2026 at 6:23 PM
onclive.bsky.social
WATCH: Lucy Gilbert, MD, MSc, FRCOG, discusses data from the ROSELLA trial of relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer. @ascocancer.bsky.social #ASCO26 #gyncsm #oncology

Full video ➡️: www.onclive.com/view/dr-gilb...
Dr Gilbert on the Efficacy of Relacorilant Plus Nab-Paclitaxel in Ovarian Cancer | OncLive
Lucy Gilbert, MD, MSc, FRCOG, discusses data from the ROSELLA trial of relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer.
www.onclive.com
September 18, 2026 at 8:39 PM
onclive.bsky.social
📰 @ascocancer.bsky.social published its first living guideline on the treatment of recurrent high-grade serous and/or endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer. @jco-asco.bsky.social #gyncsm #oncology

Learn more: www.onclive.com/view/asco-is...
ASCO Issues First Living Guideline for Systemic Treatment of Recurrent Ovarian Cancer | OncLive
ASCO's first living guideline backs platinum doublets and mirvetuximab soravtansine for FRα+, high-grade platinum-resistant ovarian cancer.
www.onclive.com
September 15, 2026 at 2:11 PM
onclive.bsky.social
Sapanisertib and serabelisib plus paclitaxel received @fda.gov fast track designation for pretreated advanced PI3K/AKT/mTOR pathway–altered endometrial cancer. #gyncsm #oncology

www.onclive.com/view/fda-gra...
FDA Grants Fast Track Designation to Sapanisertib and Serabelisib Plus Paclitaxel in Advanced Endometrial Cancer | OncLive
Sapanisertib and serabelisib plus paclitaxel received FDA fast track designation for pretreated advanced PI3K/AKT/mTOR pathway–altered endometrial cancer.
www.onclive.com
August 17, 2026 at 4:34 PM
drdonsdizon.bsky.social
"more" locally advanced primary cervical cancers, give chemoRT and pembro.
For those in whom current data indicate pembro might not help, give induction chemo. 7/7

Thoughts??

#gyncsm
November 27, 2024 at 12:26 PM
renosabat.bsky.social
Practical clinical management of ocular adverse events related to Anti... sciencedirect.com/science/articl…
Take a look at our latest review about ocular toxicities o#ADCsCs i#gyncsmsm
@paoli-calmettes.bsky.social @crcm.bsky.social @oncoalert.bsky.social !
https://sciencedirect.com/science/articl…
March 2, 2025 at 8:56 AM
mtmdphd.bsky.social
Organizing Online Health Content: Developing Hashtag Collections for Healthier Internet-Based People and Communities [Jun 28, 2019] @subatomicdoc et al. @JCOCCI_ASCO ow.ly/AxNP30p1P6g #ayacsm #bcsm #btsm #gyncsm #lcsm #mmsm #pancsm #ASCO25
May 22, 2025 at 1:35 PM
mtmdphd.bsky.social
Organizing Online Health Content: Developing Hashtag Collections for Healthier Internet-Based People and Communities [Jun 28, 2019] @subatomicdoc et al. @JCOCCI_ASCO ow.ly/AxNP30p1P6g #ayacsm #bcsm #btsm #gyncsm #lcsm #mmsm #pancsm #ASCO25 #ASCOsm
May 11, 2025 at 7:10 PM
mtmdphd.bsky.social
Organizing Online Health Content: Developing Hashtag Collections for Healthier Internet-Based People and Communities [Jun 28, 2019] @subatomicdoc et al. @JCOCCI_ASCO ow.ly/AxNP30p1P6g #ayacsm #bcsm #btsm #gyncsm #lcsm #mmsm #pancsm
January 17, 2025 at 10:03 PM
mtmdphd.bsky.social
The Needs of Women Treated for Ovarian Cancer: Results From a #gyncsm Twitter Chat [4/26/18] @TLHagan @Nauthshelley @btrfly12 @mtmdphd @DrAttai @subatomicdoc @davidgrahammd @womenofteal @btrfly12 @audvin @drdonsdizon @JPCRR ow.ly/HbzI30jHJkb
The Needs of Women Treated for Ovarian Cancer: Results From a #gyncsm Twitter Chat
Purpose: Ovarian cancer is the most fatal of all gynecologic cancers, with a high relapse rate regardless of stage. Women treated for ovarian cancer, therefore, likely have supportive care needs that ...
ow.ly
November 18, 2024 at 3:57 AM
tumorijournal.bsky.social
#gyncsm #CanSky What emerges from the most recent first-line trials is that progress in advanced #ovariancancer depends not only on new treatment, but on better patient selection.
Appropriate treatment must be determined for each individual: best treatment for each patient

omny.fm/shows/tumori...
June 12, 2026 at 10:02 AM
tumorijournal.bsky.social
#gyncsm #CanSky What emerges from the most recent first-line trials is that progress in advanced #ovariancancer depends not only on new treatment, but on better patient selection.
Appropriate treatment must be determined for each individual: best treatment for each patient

omny.fm/shows/tumori...
May 28, 2026 at 2:02 PM
tumorijournal.bsky.social
#GYN #Cancer | Expectant management or conization for persistent low-grade cervical intraepithelial neoplasia: Analysis of 5-year outcomes

🔓https://journals.sagepub.com/share/S76SVMZPIET4GBD7AGCH?target=10.1177/03008916251395597

#HPV #GYNCSM
April 30, 2026 at 5:01 PM
tumorijournal.bsky.social
#GynOnc #GYNCsm | Abdominal specimen retrieval in #endometrial cancer patients with large #uteri
⬇️
Learn more at the🔓link
journals.sagepub.com/share/EDBHID...
April 21, 2026 at 2:01 PM
tumorijournal.bsky.social
#GynCsm | Preliminary data of LEPRE study - open-label, phase 3 trial across 35 European oncology centers - suggest that #letrozole maintains safety profile expected for a hormonal agent in low-grade serous #carcinoma of the ovary #LGSCO

🔗 journals.sagepub.com/share/KHFI8T...

#CanSky #OncSky
December 18, 2025 at 11:58 AM
tumorijournal.bsky.social
Dr. Giorgio Bogani presents their article #HPV -related lesions after #hysterectomy for high-grade cervical intraepithelial neoplasia and early-stage cervical cancer 👉A focus on the potential role of #vaccination

youtu.be/YSaIGH2zMR8

#GYNCSM #CanSky #OncSky
Adoption of HPV vaccination in patients having treatment for HPV-related disease
HPV-related lesions after hysterectomy for high-grade cervical intraepithelial neoplasia and early-stage cervical cancer: A focus on the potential role of va...
youtu.be
March 18, 2025 at 11:00 AM
tumorijournal.bsky.social
📌Today marks #InternationalHPVAwarenessDay
Tumori journal is proud to share the most cited article
focused on the issue👇

journals.sagepub.com/share/FREMGI...

#GYNCSM #CanSky #OncSky @oncoalert.bsky.social
March 4, 2025 at 5:01 PM